Cancer Vaccine development for Hepatocellular Carcinoma

What is HEPAVAC ?

HEPAVAC aims to develop a highly innovative, novel cancer vaccine approach to address the high unmet medical need of hepatocellular carcinoma (HCC) patients. HCC is the most common primary liver malignancy accounting for about 6% of all new cancer cases diagnosed worldwide(nearly 750,000 new cases/year), and is the third and the fifth leading cause of death from cancer globally in men and women, respectively. Given the current lack of available effective treatments, the overall prognosis for patients with HCC is poor with a dismal 5-year survival rate of approximately 5-6%, making the disease a highly important and relevant target for the development of innovative and novel therapies. In this framework, immunotherapeutic interventions, including cancer vaccines, may represent a novel and effective therapeutic tool.

Recent News

22Jun

Additional funding to IMMATICS

0 Comments
July 16, 2014, HEPAVAC’s Vice-Coordinator IMMATICS received € 22 million as final tranche of funding to complete phase 3 study... Read More →
09May

HEPAVAC consortium presents at CIMT 2014!

0 Comments
Welcome to HEPAVAC’s presentations at CIMT Annual Meeting 2014 (May 6 – May 8) in Mainz, Germany: Tuesday, May 6:... Read More →

Project’s details

Call Identifier: FP7-HEALTH-2013-INNOVATION-1
Activity code: HEALTH.2013.2.4.1-2: Strengthening the cancer patient’s immune system
Funding Scheme: Collaborative project
Project number: 602893
Total funding: 5,996,110.80 Euros
Duration: 60 Months
Starting date:1st September 2013

Back to Top